Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration) – Drugs In Development, 2024 report and make more profitable business decisions.
Corticobasal degeneration (CBD) or corticobasal syndrome (CBS) is a rare neurological disorder that causes brain cells to die or become damaged. CBD is a form of frontotemporal degeneration, a dementia that involves the loss of cognitive functions that can gradually lead to worsening of movement, speech, memory, and swallowing. Symptoms include a clumsy or useless hand, muscle stiffness, shaking hands (tremors) and muscle spasms (dystonia), and “alien” limb sensation. A brain scan such as MRI may be used to diagnose CBD. There is no cure for CBD; physical and occupational therapy and speech therapy are used to relieve the symptoms.
The Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration) drugs in development market research report provide comprehensive information on the therapeutics under development for Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 6 molecules, with 5 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Alterity Therapeutics LtdCortice Biosciences Inc
Neural Stem Cell Institute
ProMIS Neurosciences Inc
TauRx Therapeutics Ltd
Woolsey Pharmaceuticals Inc
Table of Contents
Table
Figures
Frequently asked questions